ES2195925T3 - Proceso para fabricar una formulacion de liberacion retardada. - Google Patents

Proceso para fabricar una formulacion de liberacion retardada.

Info

Publication number
ES2195925T3
ES2195925T3 ES00951802T ES00951802T ES2195925T3 ES 2195925 T3 ES2195925 T3 ES 2195925T3 ES 00951802 T ES00951802 T ES 00951802T ES 00951802 T ES00951802 T ES 00951802T ES 2195925 T3 ES2195925 T3 ES 2195925T3
Authority
ES
Spain
Prior art keywords
compound
units
polymer
inclusive
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00951802T
Other languages
English (en)
Inventor
Thomas Ciaran Loughman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kinerton Ltd
Original Assignee
Kinerton Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinerton Ltd filed Critical Kinerton Ltd
Application granted granted Critical
Publication of ES2195925T3 publication Critical patent/ES2195925T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

Un proceso para fabricar Compuesto (I), donde el Compuesto (I) comprende el Compuesto (A), y un polímero, donde el polímero comprende unidades de lactida, unidades de glicolida y unidades de ácido tartárico, donde la relación en el polímero de las unidades de lactida es desde 71% a 73% inclusive; de las unidades de glicolida es desde 26% a 28% inclu sive; y de las unidades de ácido tartárico es desde 1% a 3% inclusive; y donde el grupo amino del Compuesto (A) está unido iónicamente a un grupo carboxílico de las unidades de ácido del polímero; comprendiendo dicho proceso la etapa de hacer reaccionar una solución acuosa de Compuesto (A) con el polímero o una sal del mismo, en una mezcla de acetonitrilo y agua donde la relación de pesos entre el acetonitrilo y el agua es de aproximadamente 3 a 1, respectivamente, a una temperatura de aproximadamente 0ºC a 5ºC hasta que se complete sustan cialmente la formación del Compuesto (I).
ES00951802T 1999-08-18 2000-08-14 Proceso para fabricar una formulacion de liberacion retardada. Expired - Lifetime ES2195925T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE19990700A IES990700A2 (en) 1999-08-18 1999-08-18 Process to make a sustained release formulation

Publications (1)

Publication Number Publication Date
ES2195925T3 true ES2195925T3 (es) 2003-12-16

Family

ID=11042112

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00951802T Expired - Lifetime ES2195925T3 (es) 1999-08-18 2000-08-14 Proceso para fabricar una formulacion de liberacion retardada.

Country Status (26)

Country Link
US (1) US6893645B1 (es)
EP (1) EP1212095B1 (es)
JP (1) JP3730917B2 (es)
CN (2) CN1823736A (es)
AR (1) AR022647A1 (es)
AT (1) ATE243044T1 (es)
AU (1) AU755229B2 (es)
BR (1) BR0013349A (es)
CA (1) CA2380902C (es)
CZ (1) CZ294433B6 (es)
DE (1) DE60003438T2 (es)
DK (1) DK1212095T3 (es)
ES (1) ES2195925T3 (es)
HK (1) HK1044285A1 (es)
HU (1) HUP0202895A3 (es)
IE (1) IES990700A2 (es)
IL (1) IL148044A0 (es)
MX (1) MXPA02001415A (es)
NO (1) NO20020762L (es)
NZ (1) NZ517251A (es)
PL (1) PL199862B1 (es)
PT (1) PT1212095E (es)
RU (1) RU2211694C1 (es)
TW (1) TWI230069B (es)
WO (1) WO2001012232A2 (es)
ZA (1) ZA200202027B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203060A3 (en) * 1999-08-18 2003-11-28 Sod Conseils Rech Applic Sustained release complex of a peptide, process for its preparation and pharmaceutical composition containing the same
US7109166B1 (en) 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
EP1348444B1 (en) * 1999-08-18 2006-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Sustained release formulation of a peptide complexed with a polymer
JP5183068B2 (ja) * 2003-12-22 2013-04-17 フィンレイ，ウォーレン，エイチ 大気噴出凍結乾燥法による粉末形成
JP2008518026A (ja) 2004-10-27 2008-05-29 ユニバーシティ・オブ・デンバー 副腎皮質刺激ホルモンアナログおよびこれに関連する方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
CA2150574A1 (en) * 1993-01-06 1994-07-21 Shalaby W. Shalaby Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
ATE284413T1 (de) 1993-08-09 2004-12-15 Sod Conseils Rech Applic Therapeutische peptid derivate
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
WO1998008528A1 (en) * 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
US5972893A (en) * 1997-05-06 1999-10-26 Cedars-Sinai Medical Center Method of treating hyperprolactinemia and prolactinomas
PL342135A1 (en) 1998-01-29 2001-05-21 Kinerton Ltd Method of obtaining absorbable microparticle
EP1043079A4 (en) 1998-08-28 2005-03-16 Mitutoyo Corp AUTOMATIC DEVICE FOR WASHING WORKPIECES BEFORE MEASURING AND AUTOMATIC PRODUCTION SYSTEM EQUIPPED WITH THIS AUTOMATIC WASHING DEVICE
HUP0203060A3 (en) * 1999-08-18 2003-11-28 Sod Conseils Rech Applic Sustained release complex of a peptide, process for its preparation and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
CZ2002266A3 (cs) 2002-05-15
MXPA02001415A (es) 2002-08-12
ZA200202027B (en) 2002-12-24
CN1377283A (zh) 2002-10-30
CA2380902A1 (en) 2001-02-22
WO2001012232A2 (en) 2001-02-22
JP2003507346A (ja) 2003-02-25
CN1823736A (zh) 2006-08-30
IL148044A0 (en) 2002-09-12
DE60003438T2 (de) 2004-05-06
HUP0202895A3 (en) 2003-11-28
CZ294433B6 (cs) 2005-01-12
NO20020762L (no) 2002-04-16
DE60003438D1 (de) 2003-07-24
TWI230069B (en) 2005-04-01
IES990700A2 (en) 2001-08-22
PL354263A1 (en) 2003-12-29
EP1212095A2 (en) 2002-06-12
PL199862B1 (pl) 2008-11-28
ATE243044T1 (de) 2003-07-15
AR022647A1 (es) 2002-09-04
CA2380902C (en) 2008-08-05
WO2001012232A3 (en) 2002-04-04
RU2211694C1 (ru) 2003-09-10
RU2002106809A (ru) 2004-01-20
JP3730917B2 (ja) 2006-01-05
BR0013349A (pt) 2002-04-23
CN1246040C (zh) 2006-03-22
AU755229B2 (en) 2002-12-05
US6893645B1 (en) 2005-05-17
NO20020762D0 (no) 2002-02-15
NZ517251A (en) 2003-08-29
DK1212095T3 (da) 2003-10-06
WO2001012232A8 (en) 2002-06-06
AU6464700A (en) 2001-03-13
EP1212095B1 (en) 2003-06-18
PT1212095E (pt) 2003-10-31
HK1044285A1 (en) 2002-10-18
HUP0202895A2 (hu) 2003-02-28

Similar Documents

Publication Publication Date Title
EA200300211A1 (ru) Азабициклические соединения, способ их получения и их применение в качестве лекарственных средств, в частности в качестве антибактериальных средств
PE20120663A1 (es) Anticuerpos anti-htnf alfa cristalinos
MY134521A (en) Stable salts of o-acetylsalicylic acid with basic amino acids
HUP0102465A2 (hu) Eljárás peroxikarbonsav-monoészter vizes oldatának előállítására, az eljárással előállított oldat és alkalmazása fertőtlenítőszerként
EP1413303A4 (en) PROMOTERS FOR GROWTH IN PORK AND METHOD FOR PROMOTING GROWTH IN PORK
ES2195925T3 (es) Proceso para fabricar una formulacion de liberacion retardada.
EA200501081A1 (ru) Производные тропенола - исходный материал для получения терапевтически эффективных соединений
BR9408563A (pt) Processo para a produção de formulações sólidas contendo tensoativos de óxido de amina
AR053093A1 (es) Procedimiento de fabricacion de sertaconazol mononitrato, sertaconazol mononitrato y sertaconazol mononitrato monohidrato obtenidos con dicho proceso
HUP0001878A2 (hu) (R)-3-(N,N-diciklobutil-amino)-8-fluor-3,4-dihidro-2H-1-benzopirán-5-karboxamid-hidrogén tartarát, eljárás előállítására és ezt tartalmazó gyógyszerkészítmények
AR029002A1 (es) Proceso para preparar compuestos de acidos quinolin-2-carboxilicos y de sus sales farmaceuticamente aceptables
BRPI0013750B8 (pt) intermediários para a produção de derivados de ácido naftiridina-3-carboxílico
ES2170910T3 (es) Procedimiento para la preparacion de oxido de rosas.
CU23441A3 (es) Composición agroquímica en suspensión acuosa
ATE275577T1 (de) Quinapril magnesium enthaltende, pharmazeutisch wirksame zusammensetzung
AR020056A1 (es) Proceso para la preparacion de derivados del acido beta - amino - 3,5 - dihalo - 2 - hidroxi - bencen - propanoico asimetricos y dichos compuestos.
BR9915684A (pt) Semicloridrato de ácido 8-cian-1-ciclopropil-7-(1s,6s-2,8-diazabiciclo-[4.3.0]-non an-8-il)-6-flúor-1,4-dihidro-4-oxo-3-quinolinocarboxìli co
WO2003063858A3 (fr) Derives de l'acide haloacetamidobenzoique et leur utilisation pour le traitement de maladies parasitaires
BRPI0407073A (pt) ésteres de ácido carboxìlico de compostos farmacêuticos
WO2004032854A3 (en) Pharmaceutical compositions for treatment of parkinson's disease
SE7910590L (sv) Antiinflammatoriska medel
ES2196926T3 (es) Procedimiento para la preparacion de disolucion concentrada fluida de betaina.
AR005903A1 (es) Un proceso para la preparacion de clorhidrato en n(g)-monometil-l-arginina
JPS5731657A (en) Di l-cysteine l-malic acid salt and its preparation
ECSP972029A (es) Proceso quimico (proceso para preparar clorhidrato de ng monometil-n-arginina)